Thursday, March 29, 2012
Europe's Innovative Medicines Initiative has
recruited 7 pharmas to each contribute up to 50,000 compounds from their
proprietary libraries and is pooling the molecules into a public-private
partnership called the European Lead Factory. The pharmas will have access to
an expanded chemical space, and academic members of the factory will be able to
run experiments with molecules that are much higher in quality than what is
typically found in academia.
Lou, K.-J. SciBX 5(13);
doi:10.1038/scibx.2012.325 Published online March 29, 2012
AND INSTITUTIONS MENTIONED
AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K.
(Xetra:BAY), Leverkusen, Germany
European Federation of Pharmaceutical Industries and
Innovative Medicines Initiative, Brussels, Belgium
H. Lundbeck A/S (CSE:LUN), Copenhagen, Denmark
Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J.
Merck KGaA (Xetra:MRK), Darmstadt, Germany
(Euronext:SAN; NYSE:SNY), Paris, France
(Euronext:UCB), Brussels, Belgium